Arrowhead Pharmaceuticals, Inc.
ARWR
|
$22.62
0.4%
0.4%
1.3M
|
Health Technology
(0.0% 1d) (-14.8% 1m) (-22.3% 1y) (0.0% 2d) (0.0% 3d) (-4.2% 7d) (-9.36% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 2,802,548,195
http://www.arrowheadpharma.com
Sec Filling | Patents | 232 employees
(US) Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
msa
add to watch list Paper trade email alert is off
Press-releases
Turnstone Biologics Appoints William Waddill to its Board of Directors
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
TSBX | $2.69 0.0% 110K
|
|
| O: 2.49%
H: 4.17%
C: -2.78%
PTGX | $25.23 -1.33% -1.35% 390K
|
Health Technology
|
| O: -1.05%
H: 0.38%
C: -0.72%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: -1.17%
H: 2.57%
C: -0.25%
ANNX | $4.435 -3.27% -3.38% 1.4M
|
Health Technology
|
| O: -3.48%
H: 2.89%
C: -7.67%
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.37%
H: 2.34%
C: 2.12%
presentation pharmaceuticals program
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.14%
H: 5.63%
C: -0.39%
treatment pharmaceuticals study
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
Published: 2024-01-22 (Crawled : 00:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.24%
H: 0.3%
C: -1.89%
first pharmaceuticals results
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
Published: 2024-01-03 (Crawled : 19:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 5.29%
H: 5.07%
C: -2.08%
million offering pharmaceuticals
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
Published: 2023-12-21 (Crawled : 15:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.8%
H: 1.99%
C: 1.52%
disease kidney clearance pharmaceuticals study
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-20 (Crawled : 13:30) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: -0.33%
H: 0.33%
C: -6.92%
conference pharmaceuticals
In-Depth Market Analysis of Rare Genetic Disorders: Familial Chylomicronemia Syndrome (FCS), Netherton Syndrome, and Acromegaly | Key Insights by DelveInsight
Published: 2023-12-18 (Crawled : 22:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: 0.0%
OPK | $1.235 -1.2% -1.21% 4.1M
|
Health Technology
|
| O: 0.65%
H: 4.52%
C: 4.52%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.57%
H: 6.03%
C: 5.71%
rare genetic market
RNA- Based Therapeutic Market worth $29.41 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
Published: 2023-12-05 (Crawled : 15:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.6%
H: 1.1%
C: -1.18%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.27%
H: 0.12%
C: 0.12%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.01%
H: 0.39%
C: 0.19%
SLN | $21.98 1.95% 1.91% 120K
|
Health Technology
|
| O: 1.16%
H: 5.02%
C: 0.79%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: -2.13%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.37%
H: 0.21%
C: -1.05%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: -1.48%
H: 0.67%
C: -4.6%
report market
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
Published: 2023-11-29 (Crawled : 00:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: -1.7%
year pharmaceuticals results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
SNDA P 3000 | $29.61 3.35% 0.0% 30K
|
n/a
|
22:00
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M
|
Distribution Services
|
20:00
QCRH | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K
|
Health Technology
|
18:00
VUZI | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K
|
Miscellaneous
|
15:00
RELL | $10.15 2.94% 2.86% 94K
|
Electronic Technology
|
13:30
IZEA | $2.65 4.74% 4.53% 31K
|
Technology Services
|
00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M
|
Finance
|
22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M
|
Health Technology
|
16:30
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10